- Home
- IAS vs MIRM Comparison
IAS vs MIRM Comparison
Compare IAS & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAS
- MIRM
- Stock Information
- Founded
- IAS 2009
- MIRM 2018
- Country
- IAS United States
- MIRM United States
- Employees
- IAS N/A
- MIRM N/A
- Industry
- IAS Computer Software: Programming Data Processing
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- IAS Technology
- MIRM Health Care
- Exchange
- IAS Nasdaq
- MIRM Nasdaq
- Market Cap
- IAS 1.7B
- MIRM 2.1B
- IPO Year
- IAS 2021
- MIRM 2019
- Fundamental
- Price
- IAS $10.29
- MIRM $39.26
- Analyst Decision
- IAS Buy
- MIRM Strong Buy
- Analyst Count
- IAS 12
- MIRM 13
- Target Price
- IAS $16.41
- MIRM $55.77
- AVG Volume (30 Days)
- IAS 499.8K
- MIRM 421.7K
- Earning Date
- IAS 10-31-2024
- MIRM 10-31-2024
- Dividend Yield
- IAS N/A
- MIRM N/A
- EPS Growth
- IAS N/A
- MIRM N/A
- EPS
- IAS 0.01
- MIRM N/A
- Revenue
- IAS $498,161,000.00
- MIRM $264,375,999.00
- Revenue This Year
- IAS $15.16
- MIRM $72.44
- Revenue Next Year
- IAS $14.61
- MIRM $27.99
- P/E Ratio
- IAS $950.17
- MIRM N/A
- Revenue Growth
- IAS 13.60
- MIRM 128.34
- 52 Week Low
- IAS $7.98
- MIRM $23.14
- 52 Week High
- IAS $17.53
- MIRM $45.23
- Technical
- Relative Strength Index (RSI)
- IAS 32.79
- MIRM 46.09
- Support Level
- IAS $10.22
- MIRM $38.04
- Resistance Level
- IAS $11.13
- MIRM $42.79
- Average True Range (ATR)
- IAS 0.25
- MIRM 1.61
- MACD
- IAS -0.09
- MIRM 0.04
- Stochastic Oscillator
- IAS 6.28
- MIRM 40.48
About IAS Integral Ad Science Holding Corp.
Integral Ad Science Holding Corp is a digital advertising verification company. The cloud-based technology platform of the company delivers independent measurement and verification of digital advertising across all devices, channels, and formats, including desktop, mobile, connected TV, social, display, and video. Geographically, the company derives a majority of its revenue from the Americas region.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.